Tirofiban

DEA Class; Rx

Common Brand Names; Aggrastat

• Antiplatelet Agents, Cardiovascular; 
• Glycoprotein IIb/IIIa Inhibitors

Severe hypersensitivity reaction to drug (i.e., anaphylactic reactions) or excipients

History of thrombocytopenia following prior exposure to therapy

Active internal bleeding or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month

Bleeding, minor (11%)

Pelvic pain (6%)

Coronary artery dissection (5%)

Bradycardia (4%)

Dizziness (3%)

Lower extremity pain (3%)

Edema (2%)

Sweating (2%)

Bleeding, major (1-2%)

Thrombocytopenia (1.5%)

Bleeding is most common complication encountered during therapy; most bleeding associated with therapy occurs at arterial access site for cardiac catheterization; minimize use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc.

Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases risk of bleeding

Profound thrombocytopenia reported; monitor platelet counts beginning about 6 hr after treatment initiation and daily thereafter; If platelet count decreases to < 90,000/mm³, monitor platelet counts to exclude pseudothrombocytopenia; if thrombocytopenia confirmed, discontinue therapy and heparin; previous exposure to a glycoprotein (GP) IIb/IIIa receptor antagonist may increase risk of developing thrombocytopenia

While published data cannot definitively establish the absence of risk, available published case reports have not established an association with therapy during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes

There is no data on presence of drug in human milk, effects on breastfed infant, or on human milk production